#China #Shanghai #Lp(a) #Argo Biopharma #BW-20829

Argo Biopharma Advances Phase 2b Trial for siRNA Therapeutic BW-20829

Argo Biopharmaceutical Co., Ltd., a pioneering company in biotechnology focused on siRNA therapies, has achieved a significant milestone by commencing a global Phase 2b clinical trial for its innovative therapeutic candidate, BW-20829. This development marks the beginning of new hope for adults suffering from elevated Lipoprotein(a) [Lp(a)] levels and Atherosclerotic Cardiovascular Disease (ASCVD).

Launched in collaboration with Novartis, the trial's initiation is a critical step toward assessing the efficacy of BW-20829 in addressing unmet medical needs in cardiovascular health. According to the company’s press release issued on January 25, 2026, the first patient has now been dosed, setting the stage for further advancements.

Dr. Dongxu Shu, the co-founder and CEO of Argo Biopharma, expressed excitement regarding the trial: "This milestone underscores not only the strength of our discovery capabilities but also our collaboration with Novartis in delivering vital therapeutic options for patients facing serious cardiovascular conditions. With cardiovascular disease being the leading cause of death globally, advancing BW-20829 into this phase of development is crucial."

BW-20829 is built on Argo’s proprietary RADS™ platform, which enables effective gene silencing. The design aims to maximize safety while providing efficient delivery specifically to hepatic tissues. This distinguishes BW-20829 from other therapies by promising a powerful, durable solution with fewer associated risks.

The clinical trial, registered as NCT07235046, will provide data to clarify how BW-20829 affects patients with elevated Lp(a) levels. High Lp(a) is associated with an increased risk of cardiovascular disease, making the search for effective treatments essential. Argo Biopharma's endeavor represents a strategic addition to their siRNA portfolio, which currently includes several other therapeutic candidates focused on various health conditions.

Argo Biopharma's commitment to advancing innovative solutions for significant health challenges is evident in the breadth of its pipeline. The company is not only concentrated on cardiovascular disease treatments but is also expanding its research into conditions caused by viral infections and metabolic disorders, reflecting a comprehensive approach to modern medical needs.

As one of the six assets in their development pipeline reaching mid-stage global clinical testing, BW-20829's progress could potentially revolutionize treatment protocols for patients with high cardiovascular risk who do not respond adequately to existing therapies. Each milestone gained through the collaboration with Novartis aligns with Argo Biopharma’s goal of enhancing patient care through cutting-edge technology and therapeutic innovations.

This development comes at a time when advancements in RNA interference (RNAi) therapeutics are increasingly crucial for addressing various health problems. With six candidates currently in the clinical development phase, Argo Biopharma is positioning itself as a leader in the biotechnology field by pushing the boundaries of traditional treatment methodologies.

For more updates on this clinical trial and additional information about Argo Biopharma's programs, you can visit their official website. The dedication to improving health outcomes is at the core of their mission, making every breakthrough essential for the lives they aim to impact.